Top in endocrinology: FDA OKs empagliflozin for kids; hormonal effects of brain injury
Click Here to Manage Email Alerts
The FDA has approved new oral therapies for children with type 2 diabetes — empagliflozin and a combination of empagliflozin and metformin hydrochloride — for the first time in more than 20 years.
The drugs by Eli Lilly and Boehringer Ingelheim were approved as an adjunct to diet and exercise after results from a double-blind, randomized, placebo-controlled trial showed that children who received empagliflozin had a 0.2% reduction in HbA1c compared with a 0.7% increase in the placebo group at 26 weeks.
It was the top story in endocrinology last week.
Another top story was an exclusive interview with Healio | Endocrine Today Editorial Board Member Tamara Wexler, MD, PhD. Wexler drew attention to pituitary hormone deficiencies, which can present “life-altering” symptoms after acquired brain injury — even a mild concussion.
“It’s straightforward to test for pituitary hormone deficiencies, and any portion of a symptom that is directly due to a pituitary hormone deficiency should be reversible or significantly ameliorated by replacement [therapy],” Wexler said.
Read these and more top stories in endocrinology below:
FDA approves empagliflozin for use among children with type 2 diabetes
The FDA has approved two forms of empagliflozin as an adjunct to diet and exercise to improve glycemic control in children with type 2 diabetes, according to a press release. Read more.
VIDEO: Chronic hormonal effects to look for following traumatic brain injury
In this video exclusive, Tamara Wexler, MD, PhD, discusses evaluation and treatment of pituitary hormone deficiencies that can occur after acquired brain injury, from mild to severe concussions. Read more.
Higher time in range reduces risks for cardiovascular events, severe hypoglycemia in type 2 diabetes
People with type 2 diabetes who spend more time in glycemic range have lower risks for major adverse cardiovascular events, severe hypoglycemia and microvascular events, according to a post hoc analysis of the DEVOTE trial. Read more.
Teriparatide delivered by robotic pill provides higher bioavailability than injection
An oral robotic pill may provide an alternative delivery method to subcutaneous injection for teriparatide and other biologics, according to a speaker at ENDO 2023. Read more.
‘Simply stunning’: Bempedoic acid may cut CVD risk for primary prevention patients by 30%
In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse CV events by 30% compared with placebo, researchers reported. Read more.